EA200400518A1 - Способы лечения глазных неоваскулярных заболеваний - Google Patents
Способы лечения глазных неоваскулярных заболеванийInfo
- Publication number
- EA200400518A1 EA200400518A1 EA200400518A EA200400518A EA200400518A1 EA 200400518 A1 EA200400518 A1 EA 200400518A1 EA 200400518 A EA200400518 A EA 200400518A EA 200400518 A EA200400518 A EA 200400518A EA 200400518 A1 EA200400518 A1 EA 200400518A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- nonascular
- diseases
- treating eye
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
В изобретении раскрыты способы лечения глазного неоваскулярного заболевания с использованием терапии против VEGF в комбинации со второй терапией, которая ингибирует развитие глазной неоваскуляризации или разрушает аномальные кровеносные сосуды в глазах, такой как фотодинамическая терапия.Отчет о международном поиске был опубликован 2004.02.12.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33230401P | 2001-11-09 | 2001-11-09 | |
PCT/US2002/035986 WO2003039404A2 (en) | 2001-11-09 | 2002-11-08 | Methods for treating ocular neovascular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200400518A1 true EA200400518A1 (ru) | 2004-12-30 |
EA006746B1 EA006746B1 (ru) | 2006-04-28 |
Family
ID=23297643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200400518A EA006746B1 (ru) | 2001-11-09 | 2002-11-08 | Способы лечения глазных неоваскулярных заболеваний |
Country Status (26)
Country | Link |
---|---|
US (3) | US20030171320A1 (ru) |
EP (1) | EP1441743A4 (ru) |
JP (1) | JP2005511576A (ru) |
KR (1) | KR20050044372A (ru) |
CN (1) | CN1582156A (ru) |
AP (1) | AP1750A (ru) |
AR (1) | AR037307A1 (ru) |
BR (1) | BR0213975A (ru) |
CA (1) | CA2464007A1 (ru) |
CR (1) | CR7330A (ru) |
EA (1) | EA006746B1 (ru) |
EC (1) | ECSP045098A (ru) |
GE (1) | GEP20063755B (ru) |
HR (1) | HRP20040406A2 (ru) |
IL (1) | IL161327A0 (ru) |
IS (1) | IS7215A (ru) |
MA (1) | MA27145A1 (ru) |
MX (1) | MXPA04004363A (ru) |
NO (1) | NO20041882L (ru) |
OA (1) | OA12720A (ru) |
PL (1) | PL371929A1 (ru) |
RS (1) | RS35404A (ru) |
TN (1) | TNSN04081A1 (ru) |
TW (1) | TWI260327B (ru) |
WO (1) | WO2003039404A2 (ru) |
ZA (1) | ZA200402753B (ru) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001234979B2 (en) * | 2000-02-10 | 2006-07-27 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
US6942655B2 (en) * | 2001-11-13 | 2005-09-13 | Minu, Llc | Method to treat age-related macular degeneration |
US6936043B2 (en) * | 2001-11-13 | 2005-08-30 | Minu, Llc | Method to treat age-related macular degeneration |
EP1605847B1 (en) * | 2003-03-07 | 2009-09-16 | Board Of Regents, The University Of Texas System | Antibody-targeted photodynamic therapy |
CL2004001996A1 (es) * | 2003-08-08 | 2005-05-06 | Eyetech Pharmaceuticals Inc | Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion. |
US7759472B2 (en) | 2003-08-27 | 2010-07-20 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
US7575321B2 (en) * | 2003-10-30 | 2009-08-18 | Welch Allyn, Inc. | Apparatus and method of diagnosis of optically identifiable ophthalmic conditions |
CN105820160B (zh) | 2003-11-05 | 2019-02-12 | 萨可德生物科学公司 | 细胞粘着调节剂 |
US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
AU2005209201B2 (en) | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
WO2005084412A2 (en) * | 2004-03-05 | 2005-09-15 | Archemix Corp. | Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US7528106B2 (en) * | 2004-06-04 | 2009-05-05 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
EP1776474A2 (en) * | 2004-07-23 | 2007-04-25 | (Osi) Eyetech, Inc. | Detection of oligonuleotides by dual hybridization |
JP2006056807A (ja) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | 光線力学療法製剤 |
AU2012200865A1 (en) * | 2004-10-21 | 2012-03-29 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
DK1802334T3 (da) * | 2004-10-21 | 2012-10-15 | Genentech Inc | Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme |
WO2006047716A2 (en) * | 2004-10-26 | 2006-05-04 | Bioresponse Llc | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease |
AU2005309854A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Ltd. | An implant for intraocular drug delivery |
US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
EP1848431B1 (en) | 2005-02-09 | 2016-02-03 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
KR20070121754A (ko) * | 2005-03-21 | 2007-12-27 | 마커사이트, 인코포레이티드 | 질환 또는 상태의 치료를 위한 약물 송달 시스템 |
US20060293270A1 (en) * | 2005-06-22 | 2006-12-28 | Adamis Anthony P | Methods and compositions for treating ocular disorders |
WO2007037188A1 (ja) * | 2005-09-27 | 2007-04-05 | Sapporo Medical University | 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬 |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
US20090098139A1 (en) * | 2006-01-30 | 2009-04-16 | Barrett Katz | Combination therapy for the treatment of neovascular disorders |
WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
US20070248646A1 (en) * | 2006-02-16 | 2007-10-25 | Ali Hafezi-Moghadam | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
US20070218007A1 (en) * | 2006-03-17 | 2007-09-20 | Allergan, Inc. | Ophthalmic visualization compositions and methods of using same |
ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
HUE053612T2 (hu) * | 2006-06-16 | 2021-07-28 | Regeneron Pharma | Intravitreális bevitelre alkalmas VEGF-antagonista készítmények |
US8668676B2 (en) * | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
US9039761B2 (en) | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
WO2008103320A1 (en) * | 2007-02-16 | 2008-08-28 | Novacea, Inc. | Methods of treating ophthalmic disorders with anthraquinones |
JP2008308489A (ja) * | 2007-05-11 | 2008-12-25 | Santen Pharmaceut Co Ltd | ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤 |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
WO2010045506A2 (en) * | 2008-10-16 | 2010-04-22 | Kathleen Cogan Farinas | Sustained drug delivery system |
US8530189B2 (en) * | 2008-10-16 | 2013-09-10 | Kathleen Cogan Farinas | Sustained drug delivery system |
JP5988584B2 (ja) | 2008-12-16 | 2016-09-07 | キュー エル ティー インク.QLT Inc. | 眼の状態に関する光線力学的療法 |
US8545554B2 (en) * | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
EP2393513B1 (en) | 2009-02-06 | 2016-10-19 | The General Hospital Corporation | Methods of treating vascular lesions |
WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
ES2468827T3 (es) * | 2010-01-14 | 2014-06-17 | Sanwa Kagaku Kenkyusho Co., Ltd | Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada |
US20130225603A1 (en) * | 2010-09-27 | 2013-08-29 | Serrata Llc | Mdm2 inhibitors for treatment of ocular conditions |
KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
CN103391782A (zh) | 2011-02-02 | 2013-11-13 | 公立大学法人名古屋市立大学 | 用于预防或治疗伴有眼内血管新生及/或眼内血管渗透性过高的疾病的药物 |
KR101303920B1 (ko) * | 2011-04-26 | 2013-09-05 | 서울대학교산학협력단 | 프로토포르피린 IX 구조를 갖는 화합물을 포함하는, 저산소상태 유도성인자1α 또는 혈관내피세포성장인자 과다 발현으로 기인하는 질병의 예방 및 치료에 유용한 조성물 |
TW201406707A (zh) | 2012-05-04 | 2014-02-16 | Acucela Inc | 用以治療糖尿病性視網膜病變及其他眼部疾病之方法 |
AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
CN103721257B (zh) * | 2012-10-16 | 2016-12-21 | 无锡兆真辐射技术有限公司 | 光敏素催化分解过氧化氢系列药物 |
RS62243B9 (sr) | 2012-11-15 | 2022-11-30 | Apellis Pharmaceuticals Inc | Analozi kompstatina sa produženim trajanjem dejstva i njihove kompozicije i postupci |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
RU2527360C1 (ru) * | 2013-04-23 | 2014-08-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ комбинированного лечения ретиноваскулярного макулярного отека |
BR112016000546A2 (pt) | 2013-07-12 | 2017-11-21 | Ophthotech Corp | métodos para tratar ou prevenir condições oftalmológicas |
WO2015099838A2 (en) | 2013-12-24 | 2015-07-02 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
RS64725B1 (sr) | 2015-12-03 | 2023-11-30 | Regeneron Pharma | Postupci dovođenja u vezu genskih varijanti sa kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije lečenih anti- vegf-om |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CN116059313A (zh) | 2017-04-07 | 2023-05-05 | 阿佩利斯制药有限公司 | 给药方案以及相关组合物和方法 |
DE102017008721A1 (de) | 2017-09-16 | 2019-03-21 | protectismundi GmbH | Verfahren und Vorrichtung zur Hochhausbrandbekämfpung |
WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
CN113101530B (zh) * | 2021-04-14 | 2022-09-30 | 中国人民解放军陆军特色医学中心 | 一种通过无线充电激活玻璃体腔植入性发光二极管的*** |
CN118108804B (zh) * | 2024-04-26 | 2024-06-25 | 山东大学 | 一种缺氧敏感功能化修饰的抗血管生成多肽、纳米胶束材料及其制备方法与应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5342348A (en) * | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
CA2536069C (en) * | 1994-03-14 | 2008-06-03 | Massachusetts Eye And Ear Infirmary | Use of green porphyrins in ocular diagnosis and therapy |
US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
JP3845469B2 (ja) * | 1996-02-21 | 2006-11-15 | 明治製菓株式会社 | 眼底の新生血管の閉塞に用いる投与剤 |
US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
DK0957929T3 (da) * | 1996-10-25 | 2006-07-03 | Gilead Sciences Inc | Vaskulær endotelial vækstfaktor (VEGF) nukleinsyreligandkomplekser |
US6123923A (en) * | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
JP2003519670A (ja) * | 2000-01-12 | 2003-06-24 | ライト サイエンシーズ コーポレイション | 眼疾患の新規処置 |
AU2001234979B2 (en) * | 2000-02-10 | 2006-07-27 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
EP1938799B1 (en) * | 2000-03-10 | 2013-05-08 | Insite Vision Incorporated | Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof |
IL151833A0 (en) * | 2000-03-24 | 2003-04-10 | Novartis Ag | Improved treatment of neovascularization |
US6936043B2 (en) * | 2001-11-13 | 2005-08-30 | Minu, Llc | Method to treat age-related macular degeneration |
AU2003301267A1 (en) * | 2002-10-18 | 2004-05-04 | The Regents Of The University Of California | Photodynamic therapy for ocular neovascularization |
-
2002
- 2002-11-08 OA OA1200400130A patent/OA12720A/en unknown
- 2002-11-08 TW TW091132890A patent/TWI260327B/zh not_active IP Right Cessation
- 2002-11-08 JP JP2003541500A patent/JP2005511576A/ja active Pending
- 2002-11-08 GE GE5563A patent/GEP20063755B/en unknown
- 2002-11-08 CN CNA028219562A patent/CN1582156A/zh active Pending
- 2002-11-08 IL IL16132702A patent/IL161327A0/xx unknown
- 2002-11-08 CA CA002464007A patent/CA2464007A1/en not_active Abandoned
- 2002-11-08 RS YU35404A patent/RS35404A/sr unknown
- 2002-11-08 BR BR0213975-8A patent/BR0213975A/pt not_active IP Right Cessation
- 2002-11-08 EA EA200400518A patent/EA006746B1/ru not_active IP Right Cessation
- 2002-11-08 AP APAP/P/2004/003026A patent/AP1750A/en active
- 2002-11-08 MX MXPA04004363A patent/MXPA04004363A/es not_active Application Discontinuation
- 2002-11-08 EP EP02802885A patent/EP1441743A4/en not_active Withdrawn
- 2002-11-08 PL PL02371929A patent/PL371929A1/xx not_active Application Discontinuation
- 2002-11-08 WO PCT/US2002/035986 patent/WO2003039404A2/en active Application Filing
- 2002-11-08 KR KR1020047006990A patent/KR20050044372A/ko not_active Application Discontinuation
- 2002-11-08 US US10/291,091 patent/US20030171320A1/en not_active Abandoned
- 2002-11-11 AR ARP020104328A patent/AR037307A1/es unknown
-
2004
- 2004-02-25 US US10/786,491 patent/US20040167091A1/en not_active Abandoned
- 2004-04-07 IS IS7215A patent/IS7215A/is unknown
- 2004-04-08 ZA ZA200402753A patent/ZA200402753B/en unknown
- 2004-04-29 MA MA27662A patent/MA27145A1/fr unknown
- 2004-04-30 CR CR7330A patent/CR7330A/es not_active Application Discontinuation
- 2004-05-07 HR HR20040406A patent/HRP20040406A2/hr not_active Application Discontinuation
- 2004-05-07 TN TNP2004000081A patent/TNSN04081A1/fr unknown
- 2004-05-07 NO NO20041882A patent/NO20041882L/no not_active Application Discontinuation
- 2004-05-07 EC EC2004005098A patent/ECSP045098A/es unknown
-
2006
- 2006-07-24 US US11/491,818 patent/US20070027101A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003039404A2 (en) | 2003-05-15 |
CR7330A (es) | 2005-06-15 |
OA12720A (en) | 2006-06-27 |
ZA200402753B (en) | 2005-01-05 |
MXPA04004363A (es) | 2005-05-16 |
US20040167091A1 (en) | 2004-08-26 |
EA006746B1 (ru) | 2006-04-28 |
BR0213975A (pt) | 2005-05-10 |
IS7215A (is) | 2004-04-07 |
HRP20040406A2 (en) | 2005-02-28 |
AP2004003026A0 (en) | 2004-06-30 |
RS35404A (en) | 2006-10-27 |
MA27145A1 (fr) | 2005-01-03 |
EP1441743A2 (en) | 2004-08-04 |
JP2005511576A (ja) | 2005-04-28 |
IL161327A0 (en) | 2004-09-27 |
NO20041882L (no) | 2004-05-07 |
PL371929A1 (en) | 2005-07-11 |
CN1582156A (zh) | 2005-02-16 |
AP1750A (en) | 2007-06-23 |
CA2464007A1 (en) | 2003-05-15 |
TW200302226A (en) | 2003-08-01 |
KR20050044372A (ko) | 2005-05-12 |
ECSP045098A (es) | 2004-07-23 |
EP1441743A4 (en) | 2009-02-25 |
US20070027101A1 (en) | 2007-02-01 |
AR037307A1 (es) | 2004-11-03 |
TNSN04081A1 (fr) | 2006-06-01 |
TWI260327B (en) | 2006-08-21 |
WO2003039404A3 (en) | 2004-02-12 |
GEP20063755B (en) | 2006-02-27 |
US20030171320A1 (en) | 2003-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200400518A1 (ru) | Способы лечения глазных неоваскулярных заболеваний | |
WO2005020972A3 (en) | Combination therapy for the treatment of ocular neovascular disorders | |
WO2004004757A8 (en) | Treatment for eye disorder | |
EA201000441A1 (ru) | Водные офтальмологические препараты | |
DE602006009834D1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
ATE554763T1 (de) | Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation | |
HK1112174A1 (en) | Control device for a surgical laser | |
DE60239931D1 (de) | Kombinationstherapie | |
AR035118A1 (es) | Metodos para disenar lentes oftalmicas multifocales | |
EA200300560A1 (ru) | Улучшенный способ лечения | |
WO2003005941A3 (de) | Insert zur behandlung des trockenen auges | |
DE502004010981D1 (de) | Intraokulare linseneinrichtung zur verbesserung des sehvermögens bei netzhauterkrankungen | |
TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
EP1808158A3 (en) | Presbyopia treatment by lens alteration | |
BR0214957A (pt) | Miméticos de superóxido dismutase para o tratamento de distúrbios e doenças oculares | |
EP1297849A4 (en) | CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES | |
PT1131073E (pt) | Uso de derivados de estaurosporina para o tratamento de doencas oculares neovasculares | |
ATE375151T1 (de) | Linderung von fehlern in der augenkontrollfunktion | |
DK1244438T3 (da) | Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde | |
AU2002351908A8 (en) | Treatment of neovascular ophthalmic disease | |
CY1118767T1 (el) | Πεπτιδια που αναστελλουν την καλλικρεϊνη του πλασματος για χρηση στη θεραπεια οφθαλμικων διαταραχων | |
BRPI0411427A (pt) | formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica | |
DK1235573T3 (da) | Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme | |
WO2002015942A8 (en) | Method for the identification of agents that inhibit or promote cataracts and uses thereof | |
WO2004073499A3 (en) | Diagnosis of primary open angle glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |